|
Xaluritamig Clinical Trials
5 actively recruiting trials across 4 locations
No change since May 2026
Also known as: AMG 509
Pipeline
Phase 1: 4Phase 3: 1
Top Sponsors
- Amgen5
Indications
- Cancer5
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)1
- Metastatic Castration-resistant Prostate Cancer, mCRPC1
- Metastatic Castration-resistant Prostate Cancer1
- Ewing Sarcoma1
San Francisco, California2 trials
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
University of California San Francisco
Phase 1
Goodyear, Arizona1 trial
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
City of Hope Cancer Center Phoenix
Phase 3
Los Angeles, California1 trial
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Cedars Sinai Medical Center
Phase 1
Irving, Texas1 trial
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Next Oncology - Dallas
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.